NEW YORK, Jan. 4, 2023 /PRNewswire/ —
Report Scope:
In this report, the market has been segmented based on route of administration, therapy type and region.The report provides an overview of the global type 2 diabetes treatment market and analyses market trends.
Read the full report: https://www.reportlinker.com/p06377384/?utm_source=PRN
Using 2021 as the base year, it provides estimated market data for the forecast period of 2022 to 2027.Revenue forecasts for this period are segmented based on route of administration, therapy type and geography.
Market values have been estimated based on the total revenue of type 2 diabetes therapies providers.
The report covers the market for type 2 diabetes treatment with regard to the therapy type across different regions.It also highlights major trends and challenges that affect the market and the vendor landscape.
It estimates the global market for type 2 diabetes treatment in 2021, and then provides projections for the expected market size through 2027.
The scope of the study includes the various types of medicines involved in type 2 diabetes treatment and management. Blood glucose monitoring, diagnostic systems and devices, and insulin-delivery devices used in the treatment of type 2 diabetes, however, have been excluded from this study.
Report Includes:
– A comprehensive overview of the global market for the treatment of type 2 diabetes
– Analyses of the global and regional market trends, with historic revenue data from 2019 to 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
– Understanding of the current and future market potential for this innovation driven market, and areas of focus to forecast the market into various segments and sub-segments
– Discussion of the industry growth driving factors and challenges that will shape the market for type 2 diabetes treatment as the basis for projecting demand in the next few years (2022-2027)
– Estimation of the actual market size and revenue forecast for global type 2 diabetes treatment market, and corresponding market share analysis by therapy type, route of administration, end user, and region
– Holistic review of the COVID-19 pandemic implications on the global market for treatment of type 2 diabetes
– Review of the patent grants and patent applications on type 2 diabetes treatment solutions and related technologies
– Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Summary:
Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood.Type 2 diabetes is one of the greatest modern health challenges.
It impacts every country and contributes to millions of deaths annually, and the number of people who suffer from this disorder is rising across all regions.According to the International Diabetes Federation (IDF), in 2021, more than REDACTED people had type 2 diabetes, and this number will reach more than REDACTED by 2045.
The drivers influencing the increase in diabetes include the aging population, increasing urbanization in underdeveloped countries, sedentary lifestyles and greater consumption of unhealthy foods linked with obesity.There is currently no cure for type 2 diabetes, but losing weight, eating healthy foods and being active can help prevent, delay and manage diabetes.
Several classes of medications and/or therapies have been developed to help people with type 2 diabetes to control their blood sugar.
The global market for type 2 diabetes treatment was estimated to be $REDACTED in 2021.It is projected the type 2 diabetes treatment market will grow at a compound annual growth rate (CAGR) of REDACTED%, and it is forecast to reach $REDACTED by 2027.
An expanding patient population, accelerating innovation and presence of significant unmet need in type 2 diabetes treatment are some of the key factors driving the growth of the current treatment market.Given the high unmet need in treatment, healthcare companies are pushing the boundaries of research and science to improve type 2 diabetes care, fueling market growth.
Loss of exclusivity, genericization, pricing pressure and evolving regulatory scenarios, however, are hindering market growth.
In this report, the global type 2 diabetes treatment market has been segmented based on route of administration, therapy type and geography.The route of administration segment has been categorized into injectable therapies and oral medications.
The oral medications segment, which currently constitutes a larger share of the market, was estimated to be valued at $REDACTED in 2022.It is estimated the oral medications market for type 2 diabetes treatment will grow at a CAGR of REDACTED%, and it is forecast to reach $REDACTED by 2027.
The injectable therapies market is further divided into insulin therapy and glucagon-like peptide-1 (GLP-1) therapy. The oral medications market is further segmented into dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, (GLP-1) receptor agonists and other oral antidiabetic medications (OADs).
The therapy type segment has been categorized into insulin therapy and non-insulin therapies.The non-insulin therapies market dominated the type 2 diabetes treatment market, with a value of $REDACTED in 2021.
This market is projected to reach $REDACTED in 2027.
Read the full report: https://www.reportlinker.com/p06377384/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
View original content:https://www.prnewswire.com/news-releases/type-2-diabetes-treatment-global-market-outlook-301712443.html
SOURCE Reportlinker
Yahoo Finance's Dave Briggs discusses General Electric's health care spinoff hitting public markets on Wednesday.
A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.
Texas has long been a priority for HCA, with the company announcing last year plans to build five new hospitals in the state.
As 2023 starts gearing up for the long haul, Wall Street is still taking a bearish view of the markets. We’re still dealing with the same headwinds, a combination of stubbornly high inflation, rapidly rising interest rates, gloomy economic indicators, the continuing war in Ukraine, uncertainty over China’s lockdown policies, a supply chain that is only slowly unsnarling itself… the list can go on. But despite the grim outlook right now, there are still some signals that give reasons for longer-t
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
(Bloomberg) — General Electric Co.’s former medical-equipment business surged in its trading debut as investors got their first chance to bet on the now-independent company.Most Read from BloombergShopify Tells Employees to Just Say No to MeetingsChina’s Foreign Minister Says ‘Deeply Impressed’ With AmericansFed Affirms Inflation Resolve, Pushes Back Against Rate-Cut BetsBattered by Covid, China Hits Pause on Giant Chip Spending Aimed at Rivaling USShares of GE HealthCare Technologies Inc. rose
A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021
RedHill Biopharma Ltd (NASDAQ: RDHL) announced the publication of positive data from a Phase 2 study RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases. The study showed that RHB-107 met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and a 100% reduction
Biogen and Eisai are jointly developing lecanemab. A decision on accelerated approval is expected by Friday.
Let's take a closer look at these three healthcare stocks defying the current bear market. Shares for TransMedics Group rose 222% in 2022. The price jump was due in part to the company's financial performance and partly to its extended moat as the only organ transplant system approved by the Food and Drug Administration (FDA) to transport multiple organs.
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.
The generic version of Paxlovid, the Pfizer-made antiviral drug that is the best treatment choice for patients at risk of developing severe covid, will soon be available in low-and middle-income countries.
Lucy Beall is a model and advocate who brings awareness to the rare condition epidermolysis bullosa
The global health body is now trying to figure out how severe the sub-variant is.
Charlotte Webster-Salter, 27, began suffering from recurring ulcers in 2018 but put it down to working long shifts as a flight attendant
Photo Illustration by Erin O'Flynn/The Daily Beast/Getty ImagesBuffalo Bills safety Damar Hamlin suffered cardiac arrest and collapsed after making a tackle during a Monday Night Football game versus the Cincinnati Bengals. While most saw a tragedy, anti-vaxxers saw opportunity.As of this writing, the reason Hamlin’s heart stopped remains unknown—one possibility raised by cardiologists is an arrhythmia caused by blunt impact to the chest—but that didn’t stop conspiracy theorists from baselessly
If we continue to be a society focused on individualism rather than community or public health I am afraid we will lose this fight.
The new XBB.1.5 COVID-19 mutation is popping up in new cases across the country at a concerning speed. Health experts weigh in on the latest variant of the virus.
Conservative pundit Charlie Kirk leaped at the chance to spread conspiracy theories and medical misinformation